STOCK TITAN

Xeris Biopharma Holdings (XERS) Stock News

XERS NASDAQ

Xeris Biopharma Holdings, Inc. reports news about its commercial biopharmaceutical business, including product revenue, financial guidance and operating updates tied to Recorlev®, Gvoke® and Keveyis®. The company commercializes Recorlev for endogenous Cushing’s syndrome, Gvoke ready-to-use liquid glucagon for severe hypoglycemia and Keveyis for primary periodic paralysis.

Recurring updates also cover development of XP-8121, a Phase 3-ready once-weekly subcutaneous levothyroxine candidate for hypothyroidism, and programs using Xeris’ XeriSol® and XeriJect® technology platforms. Company news includes intellectual property developments for Recorlev, partnership-related revenue, and equity inducement grants under Nasdaq listing rules.

Rhea-AI Summary

Xeris Biopharma (Nasdaq: XERS) reported third-quarter 2026 revenue of $107.2 million, up 44% from the same period last year. Net income rose to $11.3 million from $0.6 million, and gross margin improved to 88% from 85%. Recorlev revenue increased 93% to $71.540 million, while Gvoke revenue fell 14% following a one-time $4 million gross-to-net adjustment.

Xeris raised full-year 2026 revenue guidance to $395 million–$405 million and its 2030 revenue outlook to more than $1 billion from approximately $750 million. Nine-month revenue grew 37% to $282.5 million, but net loss widened to $17.6 million from $10.5 million, reflecting a second-quarter non-cash convertible-note charge. All 2028 convertible notes were retired in July. Xeris expects to initiate the XP-8121 pivotal Phase 3 Cornerstone study by year-end 2026, with topline data expected in late 2028 and potential approval and launch in 2030.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.05%
Tags
-
Rhea-AI Summary

Xeris Biopharma Holdings (Nasdaq: XERS) appointed Menassie M. Taddese to its Board of Directors, adding an experienced biopharmaceutical executive. The appointment is effective November 2, 2026. Taddese will also serve on the Board’s Audit Committee.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.04%
Tags
management
-
Rhea-AI Summary

Xeris Biopharma Holdings (XERS) will release third-quarter 2026 financial results and business highlights before U.S. markets open on November 5, 2026. The results cover the quarter ended September 30, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss financial and operational results and business highlights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.70%
Tags
earnings date
Rhea-AI Summary

Xeris Biopharma (XERS) announced clinical and scientific presentations covering its commercial therapies and hypothyroidism research at three scientific meetings this fall. Gvoke research presented October 9 examined the gap between clinician awareness of glucagon prescribing guidelines and prescribing practices.

A Recorlev case study scheduled for October 15–16 reports cortisol normalization and improvements in cardiometabolic measures in a patient with difficult-to-control diabetes and hypertension. A November 6 presentation at the American Thyroid Association meeting will characterize a real-world hypothyroid population using linked oral levothyroxine treatment records and thyroid-stimulating hormone laboratory data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
none
-
Rhea-AI Summary

Xeris Biopharma Holdings (XERS) granted equity awards covering 352,170 common shares to new employees on October 1, 2026.

The grants cover 60 employees and include options to purchase 64,393 shares at $9.25 per share, the closing share price on the grant date, plus restricted stock units. Both award types vest in equal annual installments over three years, subject to continued employment. The grants were made under Xeris’ Inducement Equity Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.56%
Tags
none
-
Rhea-AI Summary

Xeris Biopharma (XERS) will host an XP-8121 Program Overview webinar today, September 9, at 10 a.m. ET to present its development and commercialization plans for XP-8121, an investigational once-weekly subcutaneous levothyroxine for hypothyroidism. The company plans to initiate Cornerstone, a Phase 3 registrational trial, by year-end, with topline results expected in late 2028 and, if successful, U.S. FDA approval and launch anticipated in 2030. Xeris expects XP-8121 to have peak net revenue potential of $1 to $3 billion.

The Cornerstone trial will randomize about 500 adults and adolescents with well-controlled hypothyroidism 1:1 to XP-8121 or daily oral levothyroxine for 54 weeks across more than 50 U.S. sites. The primary endpoint is the proportion of subjects with thyroid-stimulating hormone in the normal range at both weeks 48 and 54, with a 15% non-inferiority margin and more than 90% power. Additional studies include Capstone in pediatric patients, Touchstone in difficult-to-control patients, and real-world evidence analyses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.08%
Tags
none
Rhea-AI Summary

Xeris Biopharma (Nasdaq:XERS) announced a Program Overview webinar for XP-8121, its Phase 3-ready, once-weekly subcutaneous levothyroxine injection for hypothyroidism. The event will be held on Wednesday, September 9, 2026, at 10 a.m. ET and will feature a leading endocrinologist and Xeris program leaders.

Topics include unmet medical needs in hypothyroidism, XP-8121’s market opportunity, and plans for the Phase 3 registrational program, covering trial design, endpoints, target patient population, development milestones, and anticipated regulatory timelines. A replay will be available after the live presentation, and advance registration is encouraged.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
Rhea-AI Summary

Xeris Biopharma (Nasdaq: XERS) reported second quarter 2026 total revenue of $92.1 million, up 29% year-over-year, with net product revenue of $91.0 million, up 34%. Recorlev revenue rose 81% to $56.8 million, while Gvoke declined 4% to $22.5 million and Keveyis grew 2% to $11.7 million. Gross margin improved to 86% from 82%.

The company recorded a net loss of $31.1 million, versus a $1.9 million loss a year ago, mainly due to an approximately $31 million one-time, non-cash charge tied to 2028 Convertible Notes exchange agreements. Adjusted EBITDA was $19.3 million in Q2 and $34.4 million year-to-date. Xeris tightened full-year 2026 total revenue guidance to $385–$390 million, eliminated all outstanding 2028 Convertible Notes through exchanges and conversions, and highlighted new U.S. patent protection expected for Keveyis through at least 2039 plus an additional patent for XP-8121.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.25%
Tags
-
Rhea-AI Summary

Xeris Biopharma (Nasdaq: XERS) will release its second quarter 2026 financial results before U.S. markets open on Thursday, August 6, 2026. Management will hold a conference call and webcast at 8:30 a.m. Eastern Time the same day to review financial and operational results.

Investors can pre-register for the call via the Events section of Xeris’ investor relations website, where the live webcast, replay, and related materials will be available. Xeris develops and commercializes therapies including Recorlev, Gvoke, and Keveyis, and is advancing XP-8121 and other pipeline programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
earnings date
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
none

FAQ

What is the current stock price of Xeris Biopharma Holdings (XERS)?

Xeris Biopharma Holdings (XERS) last closed at $16.70.

What is the market cap of Xeris Biopharma Holdings (XERS)?

The market cap of Xeris Biopharma Holdings (XERS) is approximately $3.1B.